NO20091501L - Farmasoytiske sammensetninger - Google Patents
Farmasoytiske sammensetningerInfo
- Publication number
- NO20091501L NO20091501L NO20091501A NO20091501A NO20091501L NO 20091501 L NO20091501 L NO 20091501L NO 20091501 A NO20091501 A NO 20091501A NO 20091501 A NO20091501 A NO 20091501A NO 20091501 L NO20091501 L NO 20091501L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical compositions
- granules
- salt
- prepared
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001346 nilotinib Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
Det beskrives et farmasøytisk preparat, særlig kapsler, omfattende granuler inneholdende nilotinib eller et salt derav med minst en farmasøytisk akseptabel eksipient. Granulene kan fremstilles ved en våtgranuleirngsprosess.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06121371A EP1923053A1 (en) | 2006-09-27 | 2006-09-27 | Pharmaceutical compositions comprising nilotinib or its salt |
PCT/EP2007/060165 WO2008037716A2 (en) | 2006-09-27 | 2007-09-25 | Pharmaceutical compositions comprising nilotinib or its salt |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20091501L true NO20091501L (no) | 2009-04-24 |
NO346639B1 NO346639B1 (no) | 2022-11-07 |
Family
ID=37684496
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20220946A NO347404B1 (no) | 2006-09-27 | 2007-09-25 | Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike |
NO20091501A NO346639B1 (no) | 2006-09-27 | 2007-09-25 | Farmasøytiske preparater og fremgangsmåte for fremstilling derav |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20220946A NO347404B1 (no) | 2006-09-27 | 2007-09-25 | Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike |
Country Status (35)
Country | Link |
---|---|
US (2) | US8293756B2 (no) |
EP (4) | EP1923053A1 (no) |
JP (2) | JP5567340B2 (no) |
KR (2) | KR101598747B1 (no) |
CN (2) | CN104306350A (no) |
AR (1) | AR062980A1 (no) |
AU (1) | AU2007301977B2 (no) |
BR (1) | BRPI0719438B1 (no) |
CA (1) | CA2662571C (no) |
CL (1) | CL2007002766A1 (no) |
CO (1) | CO6160288A2 (no) |
CY (2) | CY1117021T1 (no) |
DK (2) | DK3984528T3 (no) |
ES (3) | ES2951547T3 (no) |
FI (2) | FI3984528T3 (no) |
HK (1) | HK1133193A1 (no) |
HR (2) | HRP20151383T4 (no) |
HU (2) | HUE028204T2 (no) |
IL (1) | IL197496A (no) |
JO (1) | JO3757B1 (no) |
LT (1) | LT3984528T (no) |
MA (1) | MA30807B1 (no) |
MX (1) | MX2009003184A (no) |
MY (1) | MY148237A (no) |
NO (2) | NO347404B1 (no) |
NZ (1) | NZ575317A (no) |
PE (2) | PE20081379A1 (no) |
PL (2) | PL2068839T5 (no) |
PT (2) | PT2068839E (no) |
RU (1) | RU2469707C2 (no) |
SI (2) | SI3984528T1 (no) |
TN (1) | TN2009000093A1 (no) |
TW (3) | TWI540128B (no) |
WO (1) | WO2008037716A2 (no) |
ZA (1) | ZA200901511B (no) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
JP2013505979A (ja) | 2009-09-28 | 2013-02-21 | メディツィニシェ ウニベルジテート ウィーン | Pdgfrベータ阻害剤の新たな使用 |
JP5948246B2 (ja) | 2009-10-23 | 2016-07-06 | ノバルティス アーゲー | Bcr−abl、c−kit、ddr1、ddr2またはpdgf−rのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法 |
JO3634B1 (ar) | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
IN2011CH01887A (no) * | 2011-06-02 | 2012-12-14 | ||
AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
CN102321073A (zh) * | 2011-08-12 | 2012-01-18 | 西安交通大学 | 一种尼罗替尼的制备方法 |
AU2012328979B2 (en) | 2011-10-28 | 2016-04-21 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
CN103930094A (zh) * | 2011-11-14 | 2014-07-16 | 诺华股份有限公司 | 即释4-甲基-3[[4-(3-吡啶基)-2-嘧啶基]氨基]-n-[5-(4-甲基-1h-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺剂型 |
US9301957B2 (en) | 2011-11-14 | 2016-04-05 | Novartis Ag | Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation |
BR112015000349A2 (pt) | 2012-07-11 | 2017-06-27 | Novartis Ag | método de tratamento de tumores estromais gastrointestinais |
US9682081B2 (en) | 2013-04-25 | 2017-06-20 | Sun Pharmaceutical Industries Limited | Pharmaceutical gastro-retentive solid oral dosage form of nilotinib |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
PT3189045T (pt) * | 2014-08-11 | 2022-03-17 | Sun Pharmaceutical Ind Ltd | Novos sais de nilotinib e polimorfos do mesmo |
US10045987B2 (en) * | 2014-08-28 | 2018-08-14 | Codexis, Inc. | Imidazoyl anilide derivatives and methods of use |
ES2935158T3 (es) * | 2016-03-17 | 2023-03-02 | Sun Pharmaceutical Ind Ltd | Composición farmacéutica de nilotinib |
CN107582531B (zh) * | 2016-07-06 | 2020-12-29 | 四川科伦药物研究院有限公司 | 一种利伐沙班固体制剂及其制备方法 |
CN107320460B (zh) * | 2017-08-04 | 2020-11-03 | 北京化工大学 | 一种尼罗替尼口服纳米制剂及其制备方法 |
CN107441094B (zh) * | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
TWI815137B (zh) | 2018-06-15 | 2023-09-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽之結晶 |
AU2021212258A1 (en) | 2020-01-31 | 2022-09-29 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
CA3181361A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
EP4355306A1 (en) | 2021-06-19 | 2024-04-24 | Helm AG | Granulate composition comprising nilotinib |
WO2023285981A1 (en) * | 2021-07-15 | 2023-01-19 | Torrent Pharmaceuticals Limited | Stable pharmaceutical liquid composition of nilotinib |
EP4122452A1 (en) | 2021-07-23 | 2023-01-25 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising nilotinib and method of manufacturing the same |
EP4260848A1 (en) | 2022-04-11 | 2023-10-18 | Lotus Pharmaceutical Co., Ltd. | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072535A (en) * | 1970-12-28 | 1978-02-07 | A. E. Staley Manufacturing Company | Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
JP3125221B2 (ja) * | 1990-09-01 | 2001-01-15 | 大正製薬株式会社 | ソファルコン含有固形製剤 |
HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
PT925294E (pt) | 1996-07-24 | 2003-04-30 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa |
ZA9710927B (en) * | 1996-12-06 | 1998-06-15 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
FR2783421B1 (fr) * | 1998-09-17 | 2000-11-24 | Cll Pharma | Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications |
FR2795961B1 (fr) * | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation |
EP2338491A3 (en) | 1999-08-03 | 2011-11-30 | Lilly ICOS LLC | Pharmaceutical composition comprising a beta-carboline |
BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
CZ20022332A3 (cs) | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
CN1674877A (zh) * | 2002-06-07 | 2005-09-28 | 兰贝克赛实验室有限公司 | 控释的多单位药物释放系统 |
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
WO2004047974A1 (en) * | 2002-11-26 | 2004-06-10 | Universiteit Gent | Process and apparatus for continuous wet granulation of power material |
KR20040076203A (ko) * | 2003-02-24 | 2004-08-31 | 주식회사 엘지생명과학 | 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법 |
WO2005011635A2 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
TR200301553A1 (tr) | 2003-09-18 | 2005-10-21 | Nobel �La� Sanay�� Ve T�Caret A.�. | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
WO2005065653A1 (en) * | 2003-12-19 | 2005-07-21 | E.I. Du Pont De Nemours And Company | Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution |
WO2006013444A1 (en) | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation |
CN101031285A (zh) * | 2004-10-01 | 2007-09-05 | 卫材R&D管理有限公司 | 含有微粒的组合物及其制备方法 |
WO2006066932A1 (en) * | 2004-12-24 | 2006-06-29 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
ES2373912T3 (es) * | 2005-01-28 | 2012-02-10 | Novartis Ag | Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulación de la actividad de quinasa tie-2. |
CA2601687A1 (en) * | 2005-02-25 | 2006-08-31 | Novartis Ag | Pharmaceutical combination of bcr-abl and raf inhibitors |
GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
GT200600315A (es) * | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
KR101462693B1 (ko) * | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
-
2006
- 2006-09-27 EP EP06121371A patent/EP1923053A1/en not_active Ceased
-
2007
- 2007-09-23 JO JOP/2007/0402A patent/JO3757B1/ar active
- 2007-09-25 RU RU2009115782/15A patent/RU2469707C2/ru active
- 2007-09-25 DK DK21194622.3T patent/DK3984528T3/da active
- 2007-09-25 ES ES21194622T patent/ES2951547T3/es active Active
- 2007-09-25 PL PL07820560.6T patent/PL2068839T5/pl unknown
- 2007-09-25 JP JP2009529688A patent/JP5567340B2/ja active Active
- 2007-09-25 FI FIEP21194622.3T patent/FI3984528T3/fi active
- 2007-09-25 ES ES15184282T patent/ES2957912T3/es active Active
- 2007-09-25 AU AU2007301977A patent/AU2007301977B2/en active Active
- 2007-09-25 ES ES07820560T patent/ES2556625T5/es active Active
- 2007-09-25 NO NO20220946A patent/NO347404B1/no unknown
- 2007-09-25 SI SI200732199T patent/SI3984528T1/sl unknown
- 2007-09-25 CN CN201410535689.8A patent/CN104306350A/zh active Pending
- 2007-09-25 KR KR1020147027439A patent/KR101598747B1/ko active IP Right Grant
- 2007-09-25 LT LTEP21194622.3T patent/LT3984528T/lt unknown
- 2007-09-25 CA CA2662571A patent/CA2662571C/en active Active
- 2007-09-25 PT PT78205606T patent/PT2068839E/pt unknown
- 2007-09-25 EP EP15184282.0A patent/EP3009128B1/en active Active
- 2007-09-25 US US12/442,544 patent/US8293756B2/en active Active
- 2007-09-25 SI SI200731724T patent/SI2068839T2/sl unknown
- 2007-09-25 MX MX2009003184A patent/MX2009003184A/es active IP Right Grant
- 2007-09-25 NO NO20091501A patent/NO346639B1/no unknown
- 2007-09-25 FI FIEP07820560.6T patent/FI2068839T4/fi active
- 2007-09-25 WO PCT/EP2007/060165 patent/WO2008037716A2/en active Application Filing
- 2007-09-25 CN CNA2007800353567A patent/CN101516344A/zh active Pending
- 2007-09-25 PL PL21194622.3T patent/PL3984528T3/pl unknown
- 2007-09-25 EP EP07820560.6A patent/EP2068839B2/en active Active
- 2007-09-25 PE PE2007001294A patent/PE20081379A1/es active IP Right Grant
- 2007-09-25 AR ARP070104231A patent/AR062980A1/es not_active Application Discontinuation
- 2007-09-25 HU HUE07820560A patent/HUE028204T2/en unknown
- 2007-09-25 DK DK07820560.6T patent/DK2068839T3/da active
- 2007-09-25 MY MYPI20091044A patent/MY148237A/en unknown
- 2007-09-25 KR KR1020097008418A patent/KR20090076931A/ko not_active Application Discontinuation
- 2007-09-25 HR HRP20151383TT patent/HRP20151383T4/hr unknown
- 2007-09-25 PT PT211946223T patent/PT3984528T/pt unknown
- 2007-09-25 BR BRPI0719438-2A patent/BRPI0719438B1/pt active IP Right Grant
- 2007-09-25 HR HRP20230753TT patent/HRP20230753T3/hr unknown
- 2007-09-25 EP EP21194622.3A patent/EP3984528B1/en active Active
- 2007-09-25 PE PE2012000043A patent/PE20120626A1/es not_active Application Discontinuation
- 2007-09-25 NZ NZ575317A patent/NZ575317A/en unknown
- 2007-09-25 HU HUE21194622A patent/HUE063083T2/hu unknown
- 2007-09-26 TW TW102144088A patent/TWI540128B/zh active
- 2007-09-26 TW TW096135768A patent/TWI428333B/zh active
- 2007-09-26 CL CL200702766A patent/CL2007002766A1/es unknown
- 2007-09-26 TW TW103101056A patent/TW201418245A/zh unknown
-
2009
- 2009-03-03 ZA ZA2009/01511A patent/ZA200901511B/en unknown
- 2009-03-09 IL IL197496A patent/IL197496A/en active IP Right Grant
- 2009-03-19 TN TN2009000093A patent/TN2009000093A1/fr unknown
- 2009-04-22 MA MA31809A patent/MA30807B1/fr unknown
- 2009-04-24 CO CO09041795A patent/CO6160288A2/es unknown
- 2009-12-04 HK HK09111400.2A patent/HK1133193A1/xx active IP Right Maintenance
-
2012
- 2012-09-21 US US13/624,354 patent/US8501760B2/en active Active
-
2013
- 2013-11-07 JP JP2013231327A patent/JP2014065715A/ja active Pending
-
2015
- 2015-12-16 CY CY20151101150T patent/CY1117021T1/el unknown
-
2023
- 2023-07-27 CY CY20231100367T patent/CY1126116T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091501L (no) | Farmasoytiske sammensetninger | |
WO2010065709A3 (en) | Hydroxamic acid derivatives, preparation and therapeutic uses thereof | |
IL233677A (en) | Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition | |
CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
WO2010030359A8 (en) | Macrocyclic hepatitis c serine protease inhibitors | |
EP2364983A4 (en) | NEW TRICYCLIC DERIVATIVE DERIVATIVES AND PHARMACEUTICAL SALTS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
IL199362A (en) | Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug | |
CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate | |
CL2007000680A1 (es) | Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc. | |
IL188069A0 (en) | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | |
WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
WO2010056039A3 (en) | Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability | |
WO2009038412A3 (en) | Beta-secretase inhibiting compounds | |
EP2212325A4 (en) | 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION | |
ATE479427T1 (de) | Pharmazeutische zusammensetzung mit candesartan- cilexetil | |
EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
FR2934780B1 (fr) | Composition pharmaceutique sous forme de granules et procede de fabrication d'une telle composition pharmaceutique. | |
ZA200806399B (en) | Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them | |
FR2903602B1 (fr) | Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation | |
DE602006018617D1 (de) | Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten | |
WO2009121946A3 (en) | Process for the preparation of optically enriched clopidogrel | |
WO2009087657A3 (en) | Stable pharmaceutical composition of duloxetine and process for its preparation | |
WO2008037224A3 (es) | Forma de dosificación de liberación controlada que contiene lercanidipina y un ácido que mejora el funcionamiento |